<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496054</url>
  </required_header>
  <id_info>
    <org_study_id>V260-021</org_study_id>
    <secondary_id>2007_020</secondary_id>
    <nct_id>NCT00496054</nct_id>
  </id_info>
  <brief_title>Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)</brief_title>
  <official_title>Evaluation of Safety,Tolerability and Immunogenicity of Vaccination With Rotateq (V260) in Healthy Infants in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To observe the safety, tolerability and immunogenicity of the administration of 3 doses of
      rotateq in healthy Indian infants between 6 weeks through exactly 12 weeks of age at entry.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies (SNA)</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G2 Serum Neutralizing Antibodies(SNA)</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G3 Serum Neutralizing Antibodies(SNA)</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G4 Serum Neutralizing Antibodies(SNA)</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in P1 Serum Neutralizing Antibodies(SNA)</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies(SNA)</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for IgA</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G1</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G2</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G3</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G4</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for P1</measure>
    <time_frame>Baseline and Approximately 6 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Gastroenteritis</condition>
  <condition>Rotavirus</condition>
  <arm_group>
    <arm_group_label>RotaTeq™ Vaccine (V260)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus Vaccine, Live, Oral, Pentavalent</intervention_name>
    <description>Pentavalent vaccine 9G1, G2, G3, G4 &amp; P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.</description>
    <arm_group_label>RotaTeq™ Vaccine (V260)</arm_group_label>
    <other_name>RotaTeq™ Vaccine</other_name>
    <other_name>V260</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 weeks through exactly 12 weeks

          -  Healthy infants

        Exclusion Criteria:

          -  Clinical evidence of active gastrointestinal illness

          -  Fever, with a rectal temperature of greater than and equal to thirty eight degree
             celsius at the time of immunization

          -  History of congenital abdominal disorders, intussusception, or abdominal surgery

          -  History of known prior rotavirus disease

          -  Known or suspected impairment of immunological function

          -  Prior administration of any rotavirus vaccine

          -  Known hypersensitivity to any component of the rotavirus vaccine, e.g. trypsin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <results_first_submitted>November 12, 2009</results_first_submitted>
  <results_first_submitted_qc>February 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2010</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III
First Patient In (FPI): 09-May-2008
Last Patient Out (LPO): 20-Nov-2008
Multi-center study
Department of Paediatrics, Kashyap Nursing Home, Mumbai.
Department of Paediatrics, KEM Hospital, Pune
Department of Paediatrics, J.K.Lon, SMS Hospital, Jaipur
Panchsheel Hospital, Delhi</recruitment_details>
      <pre_assignment_details>Open‐label, single‐arm study. Healthy infants between the ages of 6 weeks through exactly 12 weeks (≥42 to ≤84 days) at entry who did not have clinical evidence of active gastrointestinal illness; who did not have fever, with a rectal temperature of greater than and equal to 38 degrees Celsius at first vaccination were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RotaTeq™ Vaccine (V260)</title>
          <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RotaTeq™ Vaccine (V260)</title>
          <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.01" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.61" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Temperature</title>
          <units>Fahrenheit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.58" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.73" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.35" lower_limit="74.95" upper_limit="89.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exhibit a 3 Fold Rise or Greater From Baseline to Approximately 6 Months in Rotavirus Specific Serum in IgA</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.83" lower_limit="75.40" upper_limit="90.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies (SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies (SNA)</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.24" lower_limit="28.81" upper_limit="47.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G2 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G2 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.71" lower_limit="7.84" upper_limit="21.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G3 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G3 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.39" lower_limit="21.46" upper_limit="39.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G4 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G4 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.25" lower_limit="27.87" upper_limit="46.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in P1 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in P1 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.39" lower_limit="21.46" upper_limit="39.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G1 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.37" lower_limit="27.84" upper_limit="46.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G2 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G2 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.14" lower_limit="7.28" upper_limit="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G3 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G3 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.29" lower_limit="20.33" upper_limit="38.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G4 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in G4 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.35" lower_limit="25.93" upper_limit="44.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in P1 Serum Neutralizing Antibodies(SNA)</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Who Exihibit 3 Fold Rise Responses or Greater From Baseline to Approximately 6 Months in P1 Serum Neutralizing Antibodies(SNA)</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.29" lower_limit="20.33" upper_limit="38.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for IgA</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for IgA</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81" lower_limit="2.74" upper_limit="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.95" lower_limit="55.23" upper_limit="115.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for IgA</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for IgA</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgA GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="2.66" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.12" lower_limit="51.67" upper_limit="109.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G1</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G1</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G1 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.53" lower_limit="35.59" upper_limit="53.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G1 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.79" lower_limit="68.65" upper_limit="107.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G2</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G2</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.25" lower_limit="53.46" upper_limit="74.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.33" lower_limit="41.66" upper_limit="60.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G3</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G3</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G3 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.22" lower_limit="21.23" upper_limit="34.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.32" lower_limit="26.71" upper_limit="44.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G4</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G4</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G4 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.91" lower_limit="43.29" upper_limit="62.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G4 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.43" lower_limit="69.36" upper_limit="102.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for P1</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for P1</title>
          <population>The number of subjects contributing to the Full analysis set (FAS) analysis includes all subjects who had immunogenicity data</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P1 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.61" lower_limit="69.48" upper_limit="107.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P1 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.56" lower_limit="82.86" upper_limit="131.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G1</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G1</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G1 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.11" lower_limit="35.07" upper_limit="52.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G1 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.19" lower_limit="65.15" upper_limit="101.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G2</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G2</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G2 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.91" lower_limit="52.91" upper_limit="74.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G2 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.21" lower_limit="40.62" upper_limit="59.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G3</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G3</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G3 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.71" lower_limit="21.48" upper_limit="35.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G3 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.95" lower_limit="25.60" upper_limit="42.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G4</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for G4</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>G4 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.74" lower_limit="42.94" upper_limit="62.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G4 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.88" lower_limit="65.52" upper_limit="98.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for P1</title>
        <time_frame>Baseline and Approximately 6 Months</time_frame>
        <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™ Vaccine (V260)</title>
            <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
          </group>
        </group_list>
        <measure>
          <title>The Summary of Geometric Mean Titer (GMT) at Baseline &amp; Approximately 6 Months for P1</title>
          <population>The number of subjects contributing to the per protocol analysis includes all subjects who are not general protocol violators, received all 3 vaccinations at 3 separate visits scheduled at least 4 weeks (28 days) apart and had valid serology results</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>P1 GMT at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.17" lower_limit="67.27" upper_limit="105.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P1 GMT at 6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.01" lower_limit="79.28" upper_limit="126.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1. Any SAE/NSAE reported day 1 through day 14 of vaccination 2. Any serious vaccine related AE that occurred throughout the study 3. Any death 4. Any event of clinical interest (intussusception) that occurred throughout the study</time_frame>
      <desc>Parents/guardians were asked to record AEs on a standardized Vaccine Report Card (VRC) from Day 1 through Day 14 after each dose of RotaTeq™
Temperatures and any episodes of vomiting and diarrhea were recorded on the card daily from Day 1 through Day 7 after each dose
6 subjects did not report after dose 1 and were considered lost to follow-up</desc>
      <group_list>
        <group group_id="E1">
          <title>RotaTeq™ Vaccine (V260)</title>
          <description>Subjects enrolled in the study received three doses of RotaTeq™ orally at 3 separate visits 4 to 10 weeks apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="29" subjects_affected="19" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

